Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.32 |
| ▸ | UGCG | Q16739 | 1/20 | 0.32 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27461765 | 1.00 | MAPT (0.43) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL11431737 | 0.89 | MAPT (0.46) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL9327248 | 0.89 | MAPT (0.46) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL9567734 | 0.89 | MAPT (0.46) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL10372875 | 0.89 | GPR88 (0.39) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL14288987 | 0.89 | MAPT (0.44) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL10872366 | 0.88 | KMT2A (0.41) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL8113253 | 0.88 | MAPT (0.43) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL28473803 | 0.88 | MAPT (0.43) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL28435235 | 0.88 | MAPT (0.43) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0076621-B1 | AZETIDINONE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 1987-09-23 | — | — | EP | claimed |
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | MEDIVIR AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-6974802-B2 | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine | MEDIVIR AB (SE) | 2005-12-13 | — | — | US | disclosed |
| US-20030186924-A1 | Prodrugs | MEDIVIR AB | 2003-10-02 | — | — | US | disclosed |
| US-6458772-B1 | Prodrugs | MEDIVIR AB (SE) | 2002-10-01 | — | — | US | disclosed |
| EP-1054891-A1 | PRODRUGS | MEDIVIR AB (SE) | 2000-11-29 | — | — | EP | disclosed |
| EP-0366641-B1 | Novel antimicrobial quinolonyl lactam esters | NORWICH EATON PHARMA (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1996004247-A1 | PROCESS FOR MAKING ANTIMICROBIAL COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1996-02-15 | — | — | WO | disclosed |
| WO-1996004286-A1 | PROCESS FOR MAKING QUINOLONYL LACTAM ANTIMICROBIALS AND NOVEL INTERMEDIATE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1996-02-15 | — | — | WO | disclosed |
| US-5491139-A | Antimicrobial quinolonyl lactams | THE PROCTER & GAMBLE COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
| US-5434147-A | Bactericides | PROCTOR & GAMBLE PHARMACEUTICALS, INC. (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0606336-A1 | PROCESS FOR MAKING ANTIMICROBIAL QUINOLONYL LACTAMS. | PROCTER & GAMBLE PHARMA (US) | 1994-07-20 | — | — | EP | disclosed |
| US-5281703-A | Process for making antimicrobial quinolonyl lactams | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1994-01-25 | — | — | US | disclosed |
| US-5273973-A | Carbapenicillins | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1993-12-28 | — | — | US | disclosed |
| WO-1993007154-A1 | PROCESS FOR MAKING ANTIMICROBIAL QUINOLONYL LACTAMS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-04-15 | — | — | WO | disclosed |
| US-5180719-A | Microbiocides | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1993-01-19 | — | — | US | disclosed |
| US-4144391-A | REPLACING AN ACETOXY GROUP BY A SULFUR NUCLEOPHILE | ELI LILLY AND COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | UNG, HAVCR2, EIF2AK2 | MAPT 4482/4885PDE3A 1375/4885SLC22A6 834/4885 |
| US-20030186924-A1 | Prodrugs | HAVCR2, CYP7A1, IGSF11 | MAPT 3289/4885PDE3A 2205/4885SLC22A6 554/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | MAPT 4482/4885PDE3A 1375/4885SLC22A6 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.